Company Info
Phone(202) 688 6650
Year Established
1998
Ticker
AZN
Exchange
NASDAQ
Contacts
Marc DunoyerCEO
Scott Weintraub
Senior VP, U.S. Commercial Operations
Sean Christie
CFO & CAO
Fred Chereau
Senior VP, Strategy & Business Development
Todd Spalding
General Counsel
Ruth Diazaraque
VP, R&D
Company Description
Alexion, an AstraZeneca company, has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).